NewsRoom Articles - Page 49 of 207

WednesdayNov 01, 2023 10:55 am

Alarming Data Highlights Gaps in Treating People with Chronic HBV

Hepatitis B is a liver infection caused by the hepatitis B virus. This disease, which can be prevented via vaccine, spreads when blood or other body fluids from an infected individual enter the body of another. Having chronic hepatitis B increases an individual’s risk of developing cirrhosis, liver cancer or liver failure. New research, which evaluated a cohort of adult veterans in America, has determined that only about one-half started on antiviral therapy. The study was led by clinical associate professor Robert J. Wong of the Stanford University School of Medicine. The researchers’ aim was to understand chronic hepatitis B-related…

TuesdayOct 31, 2023 2:54 pm

Brand Metrics e-Commerce Companies Need to Watch

Brand metrics are qualitative and quantitative measurements markets use to analyze and track the perception, performance and strength of a brand. These assessments allow marketers to gain insight into their brand awareness, loyalty and health among a company’s target audience and general market. With competition in the e-commerce sector getting increasingly fierce by the year, proper brand positioning can help e-commerce companies stand out from the pack, more effectively attracting and retaining customers over the long-term. Marketers can use brand metrics to learn how customers feel about their company and its products, and how likely they are to purchase specific…

MondayOct 30, 2023 11:37 am

Study Identifies Immune Cells Responsible for Severe Asthma

Researchers from the University of Southampton, United Kingdom and La Jolla Institute for Immunology (LJI) have identified a group of immune cells that may be responsible for severe asthma. Identified as cytotoxic CD4+ tissue-resident memory T cells, these cells congregate in the lungs and seem to have the ability to cause the harm associated with later development of asthma. Researchers say these immune cells are especially prevalent in men and note that men who are diagnosed with asthma after age 40 often have high counts of this specific T cell in their lungs, which increases their odds of developing severe…

MondayOct 30, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020 Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action Clene received a $45.1…

MondayOct 30, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse…

FridayOct 27, 2023 12:19 pm

Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain

Researchers from Stanford Medicine have found that lung cancer cells can spread to the brain and hide from the immune system by pretending to be “baby neurons.” After originating in the lungs, these cancer cells can metastasize into the brain and avoid detection by convincing neural cells that they’re juvenile neurons through the secretion of a certain chemical signal. These cancer cells secrete a chemical message/signal that is ubiquitous during times of brain development, which attracts brain cells called astrocytes to the cells. This chemical signal encourages the astrocytes to secrete other chemical signals that protect the lung cancer cells…

FridayOct 27, 2023 9:45 am

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024 If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”) The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder PaxMedica hopes to file an…

FridayOct 27, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies Scinai will also exhibit at the upcoming BIO-Europe conference in Munich Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products,…

ThursdayOct 26, 2023 2:51 pm

Biotech Firms Register Successes in Quest for Better Pancreatic Cancer Treatments

The American Cancer Society’s Cancer Facts & Figures 2023 report revealed a 1% increase in five-year survival rates for pancreatic cancer, which increased from 11% to 12%. Released in early 2023, the report represented the first instance since 2017 that five-year survival rates for pancreatic cancer increased for two years in a row. It indicates that we are making slow but steady progress against pancreatic cancer, a hard-to-treat cancer that originates in the pancreas before spreading to other organs and tissues. In many cases, pancreatic cancer spreads to the lungs, abdominal walls, lymph nodes and bones, resulting in symptoms such…

WednesdayOct 25, 2023 12:13 pm

Four Marketing Channels that eCommerce Firms Can Leverage

In an incredibly competitive market such as e-commerce, where 90% of companies fail, marketing is key to standing out from the competition and maintaining profitability. The right marketing channel mix can help you drive traffic to your merchant sites, increase conversions and boost your virtual store’s revenue. Although billions of people buy and sell online every year, attracting and retaining customers to a platform can be incredibly difficult. Traditional marketing techniques may not translate well to e-commerce. Even with the right techniques, you may not have much marketing success if you don’t devise a proper mix of marketing channels. Search…